echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Natural Products News > A study by the Sun Yat-Sen University Academy of Sciences found that: a small molecule traditional Chinese medicine, Acoladine, down-regulates the production and activation of hepatocarcinoma myeloid-derived immunosuppressive cells (MDSC)

    A study by the Sun Yat-Sen University Academy of Sciences found that: a small molecule traditional Chinese medicine, Acoladine, down-regulates the production and activation of hepatocarcinoma myeloid-derived immunosuppressive cells (MDSC)

    • Last Update: 2021-03-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
     Recently, Dr.
    Li Lian’s laboratory and Dr.
    Zheng Limin’s laboratory of the School of Life Sciences, Sun Yat-sen University published online in the official journal "Frontiers in Immunology" (htpps//doi.
    org/10.
    3389/fimmu.
    2021.
    609295) of the International Federation of Immunological Societies (IUIS).
    The research results of the anti-tumor effect mechanism of Coladine "Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-derived Suppressor Cell Generation" Cell cancer immune response)”.
     


    Myeloid-derived suppressor cells (MDSC) are immunosuppressive cells that significantly inhibit the response of immune cells.
    These cells inhibit the activation and function of killer T cells, prevent NK cell-mediated cell killing, and induce regulation T cells promote the stemness of cancer cells, promote angiogenesis and metastasis, and affect almost all types of cancer treatment.
    Previous studies have shown that in a mouse hepatocellular carcinoma model, acoradine can reduce the ratio of MDSC in the spleen of tumor-bearing mice and the tumor.
    Preliminary studies of the Sun Yat-Sen University College of Science have observed that the differentiation of hematopoietic precursor cells in the extramedullary circulatory system exhibits myeloid cell bias, and patients with solid tumors also exhibit myeloid cell bias.
    It was further discovered that extramedullary hematopoiesis (EMH) in the spleen exhibits myeloid cell bias, which promotes the production of functional bone marrow-derived suppressor cells and plays a key role in disease progression.


    The results of this study showed that in mice carrying orthotopic and subcutaneous liver cancer tumor models, acocladine significantly reduced the accumulation and activation of MDSC in the tumor and spleen, thereby increasing the number and activity of cytotoxic T cells.
    In terms of mechanism of action, Akoladine reduces the production and activation of MDSC by down-regulating tumor-related splenic extramedullary hematopoiesis.
    Through short-term culture of hematopoietic stem cells from cord blood in vitro, it was confirmed that acocladine has an inhibitory effect on human MDSC.
    In addition, in mouse hepatocellular carcinoma animal models, acoradine and PD-1 antibody enhance the efficacy of immunotherapy.
    These findings reveal that Akoladine reduces the production and activation of MDSC by down-regulating the extramedullary hematopoiesis of the spleen, which is one of its immunomodulatory and anti-tumor mechanisms.
    This result also reveals that targeting splenic extramedullary hematopoiesis is a new idea for developing cancer drugs alone or in combination.


    Hepatocellular carcinoma is a common malignant tumor with high incidence in my country.
    According to statistics, there are about 466,000 new cases each year in my country, and the number of deaths is as high as 422,000, more than half of the world's total, seriously threatening people's lives and health.
    Dr.
    Zheng Limin and Dr.
    Li Lian from the Academy of Sciences of Sun Yat-Sen University have long been engaged in the research on the immune molecular mechanism of liver cancer and have achieved a series of internationally leading research results.
    Acoladine is an innovative drug for the treatment of hepatocellular carcinoma independently developed by Beijing Sheng Nuoji Pharmaceutical Technology Co.
    , Ltd.
    It is a multi-target immunomodulatory small molecule.
    The Phase III clinical trial of Acoladine vs.
    Cinobufasine in the first-line treatment of advanced hepatocellular carcinoma, using a composite biomarker adaptive enrichment design, has been successful recently, and Sheng Nuoji will submit a drug review to the National Medical Products Administration in the near future.
    The Center (CDE) reports and communicates issues related to product launches.
    (Bioon)


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.